Biopharmaceutical sector increases capital allocation toward AI-driven drug discovery

Major biotechnology firms are scaling investments in artificial intelligence to compress drug development timelines and reduce R&D costs. While current applications remain in the experimental or preparatory phase rather than clinical practice, the industry is positioning AI as a core component of future pharmaceutical innovation.